Form 4: Enanta Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

A top executive at Enanta Pharmaceuticals sold shares to cover tax obligations related to a restricted stock unit award.

Summary

• Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, sold 2,591 shares of common stock on December 6, 2024.
• The sale was not a discretionary transaction but rather to cover withholding taxes due from the settlement of a restricted stock unit award granted on November 23, 2022.
• The shares were sold at a weighted-average price of $8.06, with individual transactions ranging from $7.87 to $8.22.
• The sale was a 'sell to cover' transaction to satisfy tax withholding obligations.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for tax purposes, which is neither positive nor negative for the company's overall outlook.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, as they often need to sell shares to cover the associated tax liabilities.

Comparison to Industry Standards

• Similar 'sell to cover' transactions are frequently observed across the pharmaceutical and biotech industries when executives exercise stock options or restricted stock units.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also see similar transactions by their executives.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Enanta Pharmaceuticals, stock sale, insider trading, restricted stock unit, tax obligations, sell to cover, executive compensation